AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$40.00 USD
+0.33 (0.83%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $39.98 -0.02 (-0.05%) 5:42 PM ET
4-Sell of 5 4
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$40.00 USD
+0.33 (0.83%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $39.98 -0.02 (-0.05%) 5:42 PM ET
4-Sell of 5 4
A Value C Growth D Momentum B VGM
Zacks News
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Patterson Companies (PDCO) Q4 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter 2022 results benefit from strength in the Dental and Animal Health segments.
Align (ALGN) Gains From Increased Case Shipment Amid FX Woes
by Zacks Equity Research
Align Technology's (ALGN) focus on expanding its global operations, both in existing and emerging international markets, raises optimism.
AMN Healthcare Services (AMN) Stock Moves -0.92%: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $111.41, moving -0.92% from the previous trading session.
Charles River (CRL) Signs saRNA-Based Vaccine Manufacture Deal
by Zacks Equity Research
Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.
Here's Why Investors Should Retain Syneos Health (SYNH) For Now
by Zacks Equity Research
Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.
3 Reasons to Add Masimo (MASI) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Amedisys' (AMED) New Tie Up to Boost At-Home Patient Care
by Zacks Equity Research
Amedisys (AMED) strengthens its Home Health and Hospice business reach by partnering with Memorial Hermann.
Here's Why You Should Retain AngioDynamics (ANGO) Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) continues to benefit from strength in segments, but forex remains a woe.
Stryker (SYK) to Boost Presence in China Via Digital Healthcare
by Zacks Equity Research
Stryker's (SYK) participation at the WIC in China marks a milestone for the company as it can bring more Advanced Digital Healthcare solutions to the China market.
Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
Zacks.com featured highlights include Sanderson Farms, United Therapeutics, AMN Healthcare
by Zacks Equity Research
Sanderson Farms, United Therapeutics, AMN Healthcare are part of zacks Screen of the week article.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Myriad Genetics (MYGN) continues to benefit from strong testing volumes, but forex remains a woe.
McKesson's (MCK) Latest JV to Boost Cancer Treatment Options
by Zacks Equity Research
McKesson's (MCK) latest activities in the oncology care space is expected to serve a wider patient pool.
Walgreens (WBA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Robust performances across the U.S. pharmacy and retail business are likely to have contributed to Walgreens' (WBA) Q3 performance.
AMN Healthcare (AMN) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
AMN Healthcare (AMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Tandem Diabetes (TNDM) Global Pump Sales Aid, Price Issue Ails
by Zacks Equity Research
Tandem Diabetes (TNDM) is witnessing strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Here's Why You Should Invest in AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
AMN Healthcare (AMN) continues to benefit from its broad range of services.
Buy These 3 Low-Beta Stocks to Sail Through a Choppy Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. United Therapeutics (UTHR), Sanderson (SAFM) and AMN Healthcare (AMN) are well poised to gain.
New Strong Buy Stocks for June 24th
by Zacks Equity Research
AMR, SBOW, AMN, BVH, and EGLE have been added to the Zacks Rank #1 (Strong Buy) List on June 24, 2022.
Where Do Pricy Tesla Shares Go from Here?
by John Blank
As important, does the S&P500 index follow along?
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Change Healthcare (CHNG)-Luma Launch Patient Engagement Suite
by Zacks Equity Research
Change Healthcare's (CHNG) latest launch is expected to significantly improve patients' healthcare journey and create a more streamlined patient experience.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from its strength in the Animal Health business and robust product portfolio. However, stiff competition remains a woe.
BD (BDX) Integrates Innovative Solution to Boost Patient Care
by Zacks Equity Research
BD's (BDX) announcement of the implementation of BD HealthSight brings together timely monitoring to support the early detection of emerging healthcare infections, thereby improving patient care.